Innovent Biologics, Inc. (HKG: 1801)
Hong Kong
· Delayed Price · Currency is HKD 35.20
-0.80 (-2.22%)
Dec 20, 2024, 4:08 PM HKT
Innovent Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | -1,281 | -1,028 | -2,179 | -2,729 | -998.42 | -1,720 | Upgrade
|
| Depreciation & Amortization | 321.26 | 310.22 | 276.79 | 202.17 | 85.63 | 86.37 | Upgrade
|
| Other Amortization | 74.89 | 74.89 | 42.64 | 2.58 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 23.03 | 0.95 | -0.06 | 0.71 | 1.2 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 423.73 | 115.36 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -79.48 | -30.81 | -5.1 | -125.02 | -30.98 | -2.63 | Upgrade
|
| Stock-Based Compensation | 644.93 | 574.2 | 469.49 | 501.57 | 402.5 | 153.07 | Upgrade
|
| Other Operating Activities | 29.69 | -272.47 | -833.19 | 213.88 | 566.44 | -40.07 | Upgrade
|
| Change in Accounts Receivable | -353.44 | -430.62 | 393.14 | -493.03 | -225.34 | -242.53 | Upgrade
|
| Change in Inventory | 511.72 | 358.95 | -105.39 | -643.28 | -311.43 | -292.48 | Upgrade
|
| Change in Accounts Payable | 4.21 | 46.93 | 130.57 | 74.43 | 36.35 | 41.45 | Upgrade
|
| Change in Unearned Revenue | -300.36 | -138.63 | 205.04 | 105.43 | 55.12 | 123.17 | Upgrade
|
| Change in Other Net Operating Assets | 536.27 | 566.77 | -313.45 | 864.46 | 111.24 | 229.13 | Upgrade
|
| Operating Cash Flow | 555.07 | 147.81 | -1,919 | -2,025 | -307.69 | -1,664 | Upgrade
|
| Capital Expenditures | -1,221 | -1,119 | -896.9 | -1,066 | -489.02 | -365.87 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.32 | 0.05 | 0.19 | 0.1 | 0.04 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -303.55 | -262.35 | -468.6 | -781.88 | -32.63 | - | Upgrade
|
| Investment in Securities | -2,105 | -204.43 | -384.74 | -254.58 | -4,490 | -2,277 | Upgrade
|
| Other Investing Activities | 1,352 | 571.22 | 314.87 | -596.15 | -173.02 | 73.7 | Upgrade
|
| Investing Cash Flow | -2,277 | -998.66 | -1,435 | -2,698 | -5,185 | -2,569 | Upgrade
|
| Long-Term Debt Issued | - | 1,336 | 1,080 | 1,463 | 372.18 | 43 | Upgrade
|
| Long-Term Debt Repaid | - | -948.85 | -392.74 | -278.72 | -33.79 | -19.34 | Upgrade
|
| Net Debt Issued (Repaid) | -164.42 | 386.7 | 687.43 | 1,184 | 338.39 | 23.66 | Upgrade
|
| Issuance of Common Stock | 2,253 | 2,255 | 2,131 | 3,951 | 4,662 | 2,175 | Upgrade
|
| Other Financing Activities | -6.59 | -54.56 | 73.59 | -131.52 | -88.63 | -89.16 | Upgrade
|
| Financing Cash Flow | 2,082 | 2,587 | 2,892 | 5,003 | 4,912 | 2,109 | Upgrade
|
| Foreign Exchange Rate Adjustments | 22.26 | -6.88 | 118.66 | -197.14 | -569.47 | 25.27 | Upgrade
|
| Net Cash Flow | 381.69 | 1,730 | -343.24 | 83.23 | -1,150 | -2,099 | Upgrade
|
| Free Cash Flow | -665.93 | -971.58 | -2,816 | -3,090 | -796.71 | -2,030 | Upgrade
|
| Free Cash Flow Margin | -8.93% | -15.66% | -61.80% | -72.38% | -20.73% | -193.82% | Upgrade
|
| Free Cash Flow Per Share | -0.42 | -0.62 | -1.89 | -2.12 | -0.59 | -1.72 | Upgrade
|
| Cash Interest Paid | 130.23 | 127.61 | 104.88 | 78.83 | 45.83 | 41.32 | Upgrade
|
| Cash Income Tax Paid | - | -114.42 | 66.1 | 26.44 | 139.71 | -13.73 | Upgrade
|
| Levered Free Cash Flow | -176.4 | -907.54 | -2,475 | -2,612 | -806.08 | -1,622 | Upgrade
|
| Unlevered Free Cash Flow | -122.43 | -845.9 | -2,411 | -2,573 | -763.36 | -1,585 | Upgrade
|
| Change in Net Working Capital | -1,159 | -554 | -116.9 | -258.09 | 381.6 | 320.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.